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Abstract
Objectives: Saxagliptin and sitagliptin are two commonly used dipeptidyl peptidase-4 (DPP-4) inhibitors. Little is
known about their comparative effectiveness in the real world, particularly their impact on cost and resources use.
The objective of this study was to analyze charges and resource use associated with saxagliptin and sitagliptin to
understand the impact of these DPP-4 inhibitor treatment options in a real-world setting.
Methods: This was a retrospective, new-user study approved by the Institutional Review Board at the University of
Toledo. Data were collected from a US insurance claims dataset (OptumInsight) for patients newly initiating treatment
with saxagliptin or sitagliptin between January 1, 2010 and December 31, 2011. ICD-9 code 250 was used to identify
patients with T2D. Overall and diabetes-related medical and pharmacy charges were observed. Inpatient hospitalizations
were also compared. Propensity score matching was used to balance the cohorts of patients prescribed saxagliptin and
sitagliptin. Appropriate univariate statistical tests were applied to the propensity-matched sample to examine differences
in resource utilization outcomes. Statistical significance was evaluated at P < 0.05.
Result: After the propensity score matching, each cohort included 7711 patients. Saxagliptin treatment was associated
with lower overall charges ($13,292 vs $14,032; P = 0.0023) and overall medical charges ($9,540 vs $10,296; P = 0.0024)
during the 6-month follow-up period compared with sitagliptin treatment. No significant differences were observed in
the overall pharmacy charges ($3,751 vs $3,753; P = 0.6937) and the diabetes-related charges ($5,141 vs $5,232; P = 0.
2957). All-cause and diabetes-related inpatient hospitalization rates were significantly lower with saxagliptin treatment
(p = 0.0001 and p = 0.0019, respectively). All-caused inpatient charges were also significantly lower with saxagliptin
($2,917.26 vs $3445.89; P < 0.0001).
Conclusion: Compared with patients initiating sitagliptin treatment, patients initiating saxagliptin treatment reported
lower overall and medical charges and lower overall and diabetes-related hospitalization rates. These findings may aid
payers in managing patients with T2D.
Background
Type 2 diabetes mellitus (T2D) accounts for 90–95 % of
US adult cases of diabetes [1]. In 2012, the burden of di-
agnosed diabetes was estimated to be $245 billion, which
included $176 billion in direct healthcare expenditures
and $69 billion in lost productivity [2]. Biguanides (eg,
metformin) are the initial pharmacotherapy of choice for
T2D [3–5]. However, patients, particularly those with
higher baseline glycated hemoglobin (HbA1c) values,
may not achieve their glycemic goals on metformin
despite titration to the maximum tolerated dose, and
therefore may require additional medication [6–8]. As
outlined in position statements and society algorithms
from the American Diabetes Association/European
Association for the Study of Diabetes, the American
Association of Clinical Endocrinologists, and the American
College of Physicians, disease progression leads to a need
for additional antihyperglycemic agents to maintain or
improve blood glucose control [9–11]. One such class of
antihyperglycemic agents recommended to manage T2D is
the dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an
enzyme that degrades the incretins glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) [12]. These endogenous polypeptides are released in
response to nutrient intake to mediate glucose-dependent
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insulin secretion. DPP-4 inhibition prevents the inactivation
of GLP-1 and GIP, which increases levels of active GLP-1
and GIP. This increase in levels of these active incretins is
associated with increased insulin secretion (GLP-1 and
GIP) and reduction in glucagon secretion (GLP-1), thereby
lowering glucose levels. Also, since the biologic effects of
GIP and GLP-1 are glucose-dependent, the risk of
hypoglycemia is minimized [13]. The DPP-4 inhibitors
approved by the US FDA are sitagliptin (Januvia®, Merck
Sharp & Dohme Corp., Whitehouse Station, NJ), saxaglip-
tin (Onglyza®, AstraZeneca, Wilmington, DE), linagliptin
(Tradjenta®, Boehringer Ingelheim, Ridgefield, CT), and
alogliptin (Nesina®, Takeda Pharmaceuticals America, Inc.,
Deerfield, IL). Of these, saxagliptin and sitagliptin are the
two DDP-4 inhibitors that have been approved and on the
market long enough to provide sufficient claim data for cost
comparison [14].
Although both saxagliptin and sitagliptin are FDA
approved and have established their efficacy through
clinical trials [15], little is known about their compara-
tive effectiveness in the real world; more research is
needed to measure the impact on cost and resources use
[16]. Understanding the impact of these DPP-4 inhibitor
treatment options on real-world utilization and charges
may assist payers in managing these patients. Thus, the
objective of this study was to compare charges and
resource use during the 6 months following treatment
initiation with saxagliptin or sitagliptin.
Methods
Study design
This was a retrospective cohort study that used data
from a US insurance claims dataset (OptumInsight) for
patients newly initiating treatment with saxagliptin or
sitagliptin between January 1, 2010, and December 31,
2011. OptumInsight is a proprietry administrative claims
database. It contains both medical and pharmacy claims
of more than 40 million beneficiaries from both com-
mercial and public (traditional Medicare and Medicare
Advantage) insurances in 50 states. Data from outpatient
pharmacy claims included National Drug Codes (NDC)
for dispensed medications, quantity dispensed, drug
strength, days’ supply, and health plan and patient costs.
Medical claims from facilities and providers included
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnosis codes, ICD-
9 procedure codes, Current Procedural Terminology
(CPT) procedure codes, Healthcare Common Procedure
Coding System (HCPCS) procedure codes, site of service
codes, revenue center codes, provider specialty codes,
and health plan and patient costs. While processing data
it was made sure that all techniques used to access data
are compliant with the Health Insurance Portability and
Accountability Act of 1996, and no identifiable protected
health information was extracted during the course of
the study. The study was approved by the Institutional
Review Board at the University at Toledo.
Patient selection
Each patient included in this study was ≥18 years of age
and diagnosed with T2D. To identify patients with T2D,
primary or secondary ICD-9 CM codes 250.x0 or 250.x2
were used.
It was also required that patients have at least 1 prescrip-
tion claim for saxagliptin or sitagliptin between January 1,
2010, and December 31, 2011, at least 6 months of
continuous eligibility before treatment initiation (baseline
period), and at least 6 months of continuous eligibility after
treatment initiation (follow-up period).
Patients with a claim for saxagliptin or sitagliptin
during the baseline period, and patients who initiated
multiple index therapies (multiple claims of DPP4 inhib-
itors at the index period), were excluded from the study.
Patients were excluded if they were found to have both
saxagliptin and sitagliptin at index (treatment initiation
period). Combined therapy at initation was not allowed.
We used intention-to-treat design and our patient se-
lection was based on baseline information on saxagliptin
and sitagliptin. As a result, we did not exclude patients
that switched medications. Our goal was to compare
patients that are initiated on saxagliptin with those who
are initiated on sitagliptin.
Study variables
The outcome variables included charges in the individual
6-month follow-up period. These computed charges were
comprised of overall charges (i.e., both medical and
pharmacy claims), overall medical charges, and overall
pharmacy charges. The overall charges were the sum of
medical and pharmacy costs paid by health plans and pa-
tients’ out-of-pockets for all medical and pharmacy claims
for the 6-month follow-up period. Overall medical charges
included non-prescription medical claims, while overall
pharmacy charges included the total of prescription costs.
Diabetes-specific charges, such as diabetes-related
overall charges (i.e., both medical and pharmacy claims),
diabetes-related medical charges (calculated from in-
patient and outpatient claims related to diabetes), and
diabetes-related pharmacy charges, were assigned. The
claims data provided information on ICD-9 CM codes
associated with these charges. Based on medical claims
with a primary or secondary ICD-9 CM diagnosis code
for T2D and prescription claims for antidiabetes medica-
tions. Hospitalization rates in the 6-month follow-up
period were also determined; these rates included overall
inpatient hospitalization rates and diabetes-related
inpatient hospitalization rates.
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The baseline variables included the following: demo-
graphics (i.e., age, gender, and index year); comorbid
conditions in the baseline period (i.e., cardiovascular
events, obesity, dyslipidemia, stroke, atherosclerosis,
retinopathy, hypertension, nephropathy, diabetic foot
ulcer, neurologic complications, dental disease, and renal
impairment); comorbid indices (i.e., Charlson Comorbid-
ity Index [CCI], Diabetes Complications Severity Index
[DCSI8] Dichotomized as 1–4 and >5, and Psychiatry
Diagnostic Groups [PDGs7], which assessed whether a
patient belonged to any of the 12 PDG categories);
pharmacotherapy - use of any antidiabetes medication in
the baseline period (yes/no); number of classes of
antidiabetes medications used in the baseline period;
polytherapy at index with specific antidiabetes medica-
tions biguanides, thiazolidinediones, sulfonylureas,
insulin, or other polytherapy; use of other medications
in the baseline period - antihypertensives and statins;
and baseline resource utilization – copay (co-payment)
value for index drug at index date (copay of the studied
drugs at baseline period), inpatient hospitalization, and
overall charges.
Statistical analysis
Propensity score matching was used to balance the
cohorts of patients prescribed saxagliptin or sitagliptin.
Propensity scores predicting use of saxagliptin or
sitagliptin were generated using multivariate logistic
regression based on demographic characteristics, comor-
bidities in the baseline period, comorbidity indices, base-
line resources use, and baseline pharmacotherapy before
the index date. Certain variables such as DCSI were cat-
egorical, while CCI was matched as continuous variable.
Propensity score matching aims to adjust the selection
bias in nonexperimental, nonrandomized, and retro-
spective observational studies. It allows the mirroring of
each patient in the saxagliptin cohort with a patient with
similar characteristics in the sitagliptin cohort. Based on
the balancing guidelines [17], a 1:1 propensity-matched
sample of saxagliptin and sitagliptin patients produced
cohorts with more balanced baseline characteristics.
Hence, a 1:1 caliper-matching technique was created to
reduce any potential confounding. The result was that
the patients were matched using the calipers of width
equal to 0.01 of the standard deviation of the logit of the
propensity score. Although there are no specific guidelines
for the size of caliper to be used, it is advised to use a tigh-
ter caliper to reduce the bias. The study picked 0.01
caliper because it gave us maximum closeness along the
variables while maintaining the appropriate sample size.
After matching, statistical tests were conducted to
compare saxaglipitin initiaters with sitaglipitin initiators.
Variables that were normally distributed such as health-
care utilization and other independent variables were
compared using t-tests and chi-square tests However, for
cost adjusted values, a univariate generalized linear
model (GLM) with a log link function and γ distribution
for the error term was used to account for the non-
normal distributions associated with cost data . All out-
comes were assessed based on an intent-to-treat analysis
in the 6-month follow-up period. Statistical significance
was evaluated at P < 0.05. Analysis were conducted with
SAS version 9.3 (SAS Institute Inc. Cary, NC, USA).
Results
Data from 31,503 patients were used for the analyses.
Patients were divided into two cohorts each receiving
saxagliptin or sitagliptin treatment in the 6-month
follow-up period. The cohorts were balanced using the
propensity score matching technique; after propensity
score matching each cohort had 7711 patients, and no
significant differences were observed in most of the
above mentioned baseline characteristics of demographics,
comorbid conditions, comorbid indices, pharmacotherapy,
polytherapy, use of other medications in the baseline
period, disease severity proxy, and baseline resource
utilization (Table 1). However, index year, hypertension
comorbidity, copay at index date, use of biguanides, taking
antidiabetes medication at baseline, and number of anti-
diabetes medication classes were still significantly differ-
ence between two groups; but the differences are smaller
compared to the pre-matching differences. Propensity
score matching reduced the differences under 15 %. In
case of remaining variables, propensity matching helped
bring standardized differences much closer to 0, indicating
the improved covariate balance (Fig. 1).
Saxagliptin treatment was associated with lower over-
all charges ($13,292 vs $14,032; P = 0.0023) and overall
medical charges ($9,540 vs $10,296; P = 0.0024) during
the 6-month follow-up period compared with sitagliptin
treatment.
Pharmacy charges did not differ significantly between
saxagliptin treatment and sitagliptin treatment ($3,751
vs $3,735, P = 0.6937, respectively) (Fig. 2).
No significant differences were associated with diabetes-
related overall charges ($5,141 vs $5,232; P = 0.2957),
diabetes-related medical charges ($3,428 vs $3,499; P =
0.4998), and diabetes-related pharmacy charges between
saxagliptin treatment and sitagliptin treatment ($1,713 vs
$1,732, P = 0.2495, respectively) (Fig. 3).
Inpatient hospitalization rates were significantly lower
with saxagliptin treatment than with sitagliptin treatment
in terms of all-cause hospitalizations (6.6 % vs 8.1 %; P =
0.0001) and diabetes-related hospitalizations (4.67 % vs
5.78 %; P = 0.0019) (Fig. 4). All-cause inpatient charges
and diabetes-related inpatient charges were significantly
lower with saxagliptin ($2,917.26 vs $3,445.89; P < 0.0001
and $1,325.13 vs $1,342.12; P = 0.0003, respectively).
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Table 1 Baseline characteristics of patients who initiated treatment with saxagliptin or sitagliptin











Age, years, mean (SD) 54.4 (10.0) 54.8 (10.6) 0.001 54.53 (9.96) 54.58 (10.60) 0.7590
Men, % 56.6 55.9 0.265 56.28 56.63 0.6610
Index year, % <0.001 0.0132
2010 43.0 54.8 45.13 39.49
2011 57.0 45.2 54.87 60.51
Comorbidities, %
Cardiovascular disease 20.3 21.2 0.067 20.50 19.98 0.4228
Obesity 10.5 11.1 0.194 10.58 10.47 0.8133
Dyslipidemia 71.9 67.7 <0.001 71.40 72.45 0.1466
Stroke 2.9 3.3 0.126 3.00 3.00 1.000
Atherosclerosis 1.9 2.1 0.337 1.92 1.74 0.4001
Retinopathy 4.3 4.6 0.189 4.45 4.38 0.8446
Hypertension 69.7 66.1 <0.001 68.88 70.35 0.0459
Nephropathy 2.5 2.7 0.305 2.48 2.54 0.7969
Diabetic foot problems 0 0 0.432 0.03 0.03 1.000
Neurological complications 5.5 5.4 0.763 5.38 5.45 0.8588
Dental disease 0.1 0.1 0.754 0.08 0.06 0.7629
Renal impairment 6.9 7.3 0.315 6.87 6.94 0.8738
Psychiatry diagnostic group 11.0 11.6 0.147 11.18 10.43 0.1324
DCSI 1–4 27.4 27.1 0.624 27.45 26.91 0.624
DCSI ≥5 4.7 5.5 0.002 4.72 4.67 0.8790
CCI, mean (SD) 1.66 (1.35) 1.69 (1.49) <0.05 1.66 (1.35) 1.67 (1.40) 0.8292
Baseline resource use
Copay value for index drug at index date, mean (SD) 55.3 (34.4) 35.9 (27.4) <0.001 52.57 (32.64) 50.39 (33.88) <0.0001
Baseline overall charges (%) <0.001 0.7638
Quartile 1 (lowest charges) 17.7 19.2 17.66 16.95
Quartile 2 28.2 26.4 28.10 28.69
Quartile 3 30.4 28.3 30.14 30.93
Quartile 4 (highest charges) 23.7 26.1 24.10 23.43
Inpatient Hospitalizations, %
All 6.7 9.5 <0.001 7.15 6.42 0.0729
Diabetes related 4.6 6.8 <0.001 4.86 4.50 0.4785
Baseline Pharmacotherapy
Antidiabetic medications, % yes 75.9 72.1 <0.001 75.70 77.46 0.0097
Antidiabetic medication classes, mean (SD) 1.32 (1.04) 1.23 (1.03) <0.001 1.31 (1.04) 1.34 (1.02) 0.0476
Polytherapy, %
Any Polytherapy 56.3 60.8 <0.001 56.45 55.48 0.2238
Biguanides 48.4 53.5 <0.001 48.74 46.12 0.0011
Sulphonylureas 12.5 11.3 0.006 12.27 13.18 0.0907
Insulin 4.2 4.2 0.949 4.16 4.44 0.4045
Other Medications, %
Antihypertensives 68.3 66.8 0.014 67.95 68.64 0.3590
Statins 49.3 47.5 0.005 49.02 50.12 0.1710
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Discussion
The total healthcare costs attributable to T2D are
substantial. Medical costs attributed to T2D include
$27 billion for direct care, $58 billion to treat patients
with diabetes-related chronic complications, and $31
billion in excess general medical costs. Given the sig-
nificant economic burden of T2D, reducing it is of
major significance to payers. Therefore, it is in the
best interests of healthcare payers to adopt the most
cost -saving treatment strategies that would yield
maximum benefits at minimum cost. This study was
designed to inform healthcare decisions by comparing
resource utilization over a 6-month period following
initiation of one of 2 commonly prescribed DPP4 in-
hibitors in a real world setting using insurance claims
data in the US.
Research has suggested that sitagliptin and saxaglip-
tin both produce similar improvements on HbA1c
levels, from 0.5 to 1.2 %, with no increase in the risk of
hypoglycemia unless combined with other therapies
[15, 18, 19]. Assuming this clinical equivalence, other
factors such as the ease of dosing among patients with
renal impairment, tolerability, lower copays, or drug-
drug interactions might lead to a difference in the real
world cost and resource utilization between saxagliptin
and sitagliptin. In support of a possible difference in
ease-of-use, Farr et al. showed that saxagliptin is associ-
ated with greater adherence compared with sitagliptin,
which could be due to one-step adjustment with saxa-
gliptin in renally impaired patients, instead of two-step
adjustment with sitagliptin [18]. Interestingly, our study
also found that there was a small, but significant,
Fig. 1 Covariate balance
Fig. 2 Mean overall healthcare charges during the follow-up period: after propensity matching
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difference in the copays at the baseline between saxa-
gliptin and sitagliptin groups (the average difference
was $2.18). Thus, it is important to determine whether
these factors would result in the difference in real
world resource utilization between saxagliptin and
sitagliptin.
Our analysis shows that lower overall costs and in-
patient utilization within a 6-month follow-up period were
observed in patients initiating saxagliptin treatment. Over-
all charges, overall medical charges, and inpatient charges
and utilization were significantly lower in patients initiat-
ing saxagliptin treatment. Higher inpatient utilization with
sitagliptin might have contributed to higher medical
charges and higher overall charges. This is consistent with
the finding of prior research using a different database
and matching method [16]. However, diabetes-related
charges did not significantly differ between saxagliptin
and sitagliptin users in our study. This might be due to
the difficulty in determining whether a particular compli-
cation is related to diabetes by clinicians. For example,
diabetes increases the risk of many severe cardiovascular
complications. However, these complications of diabetes
can occur among patients without diabetes, and it is
difficult for clinicians to determine if a particular compli-
cation is attributable to diabetes. Consequently, the classi-
fication of diabetes-related complications is imperfect.
Using the Januvia Diabetes Economic Model (a discrete
event simulation model for long-term outcomes of
diabetes), Schwarz et al. has found sitagliptin to be more
cost-effective than thiazolidinediones and sulfonylureas
even with a high cost per day [19]. These results suggest
cost-effectiveness of DPP4 inhibitors compared with
other commonly available oral medications. saxaglip-
tin also belonging to the same category of DPP4
inhibitors, results from Januvia Diabetes Economic
model can be extrapolated to demonstrate potential
cost effectiveness of saxagliptin in a similar way.
Future research needs to study and confirm these
findings by conducting a cost-effectiveness analysis of
saxagliptin compared to other antidiabetes oral medi-
cations. It should be also noted that this analysis is
carried out using insurance claims data from a US
population and may not be generalized to other coun-
tries as the healthcare system in different countries
may differ with respect to payment system and for-
mulary structure.
Fig. 3 Mean diabetes-related healthcare charges during the follow-up period: after propensity matching
Fig. 4 Inpatient hospitalization rates during the follow-up period: after propensity matching
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Limitations
Due to selection bias, propensity score matching was used
to reduce confounding from differences in the patients’
baseline characteristics. While the majority of baseline
variables became indifferent between patients taking saxa-
gliptin and sitagliptin after matching, few variables such as
index year were still significantly different between two
groups (p < 0.05). However, these differences were reduced
after matching when compared to those before matching,
Additionally, we cannot rule out the possibility of residual
confounding, particularly due to differences in duration of
disease or severity (e.g., HbA1c), which was not available
in this database. Because clinicians likely initiate saxaglip-
tin and sitagliptin in patients with similar disease duration,
and the baseline hospitalization rates post matching do
not significantly differ between the saxagliptin and sita-
gliptin groups, the possibility of selection bias is limited.
The data may fail to generalize well to other populations.
Although the intent to treat design provides several
advantages it also adds a few limitations. One such limita-
tion is difference in end-point due to a large proportion of
participants cross over to opposite treatment arms How-
ever, in this analysis the follow up period being 6 months
such risk is a minimum. In addition Intent to treat analysis
has been criticized for being too cautious and thus being
more susceptible to type II error [20, 21].
Conclusion
Compared with patients initiating sitagliptin treatment,
patients initiating saxagliptin treatment reported lower
overall and medical charges and lower overall and diabetes-
related hospitalization rates. These findings may aid payers
in managing patients with T2D.
Competing interest
Dr. Jack Sheehan is currently employed at the AstraZeneca. Dr. Iftekhar
Kalsekar was employee of AstraZeneca at the time study was conducted.
Authors’ contributions
VV - Study design - Data analysis - Manuscript writing. KA - Data analysis -
Manuscript editing. JS - Study design - manuscript review - manuscript
revisions. IK - Study design - manuscript review - manuscript revisions. All
authors read and approved the final manuscript.
Acknowledgment
We would like to thank Dr. Duy Vu Le for his editorial support in preparation
of this paper.
Financial & competing interests disclosure
This study was funded by AstraZeneca. J Sheehan is an employee of AstraZeneca.
Iftekhar Kalsekar is past employee of AstraZeneca. The authors have no other
relevant affiliations or financial involvement with any organization or entity with a
financial interest in or financial conflict with the subject matter or materials
discussed in the manuscript apart from those disclosed.
Author details
1Health Outcomes and Socioeconomic Sciences, College of Pharmacy and
Pharmaceutical Sciences, University of Toledo, Health Science Campus, Mail
Stop # 1013, 3000 Arlington Ave., Toledo, OH 43614, USA. 2Novartis
Pharmaceuticals, Hyderabad, India. 3Health Economics and Outcomes
Research, AstraZeneca, Fort Washington, PA 19034, USA. 4Health Informatics-
Medical Devices, Johnson & Johnson, New York, NY, USA.
Received: 22 January 2016 Accepted: 15 June 2016
References
1. Diabetes: Successes and Opportunities for Population-Based Prevention and
Control At A Glance 2011. Chronic Disease Prevention and Health Promotion.
2011.
2. American Diabetes Association. Economic Costs of Diabetes in the U.S. in
2012. Diabetes Care. 2013;36(4):1033–46.
3. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15(6):755–72.
4. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15(6):737–54.
5. Fowler MJ. Diabetes Treatment, Part 2: Oral Agents for Glycemic
Management. Clinical Diabetes. 2007;25(4):131–4.
6. Nathan DM, Buse JB, Davidson MB, et al. Medical Management of
Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the
Initiation and Adjustment of Therapy: A consensus statement of the
American Diabetes Association and the European Association for the
Study of Diabetes. Diabetes Care. 2009;32(1):193–203.
7. Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B.
Long-term glycaemic control with metformin-sulphonylurea-pioglitazone
triple therapy in PROactive (PROactive 17). Diabet Med. 2009;26(10):1033–9.
8. Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients
with type 2 diabetes. Diabetes Obes Metab. 2009;11(9):844–54.
9. Garber A, Abrahamson M, Barzilay J, et al. AACE Comprehensive Diabetes
Management Algorithm 2013. Endocr Pract. 2013;19(2):327–36.
10. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of
Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach:
Position Statement of the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD). Diabetes Care.
2012;35(6):1364–79.
11. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic
treatment of type 2 diabetes mellitus: a clinical practice guideline from the
American College of Physicians. Ann Intern Med. 2012;156(3):218–31.
12. Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related
molecules in type 2 diabetes. Front Biosci. 2008;13:3648–60.
13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor
agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;
368(9548):1696–705.
14. Quarter Watch: Monitoring FDA MedWatch Reports. Perspectives on GLP-1
Agents for Diabetes. 2013.
15. Gerrald KR, Van Scoyoc E, Wines RC, Runge T, Jonas DE. Saxagliptin and
sitagliptin in adult patients with type 2 diabetes: a systematic review and
meta-analysis. Diabetes Obes Metab. 2012;14(6):481–92.
16. Kaltenboeck A, Birnbaum H, Yushkina Y, Schwiep F, Bell K, Thomas N.
Costs After Initiating Saxagliptin, Sulfonylurea, or Sitagliptin in Patients
With T2DM. Am J Pharm Benefits. 2014;6(3):e60–9.
17. Baser O. Too much ado about propensity score models? Comparing
methods of propensity score matching. Value Health. 2006;9(6):377–85.
18. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin,
vildagliptin or saxagliptin–diabetes control and potential adverse events.
Best Pract Res Clin Endocrinol Metab. 2009;23(4):487–98.
19. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011;15(4):
298–308.
20. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I.
Retrospective Analysis of Long-Term Adherence to and Persistence with
DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus. Adv Ther.
2014;31(12):1287–305.
21. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-
based treatment regimens in European patients with type 2 diabetes
and haemoglobin A1c above target on metformin monotherapy.
Diabetes Obes Metab. 2008;1:43–55.
Vaidya et al. Health Economics Review  (2016) 6:26 Page 7 of 7
